More than one-third of nonanemic patients admitted to Royal Perth Hospital in Australia developed anemia during their stay.
Researchers analyzed prospective follow-up data from 702 patients with Diamond-Blackfan anemia for cancer incidence and risk.
Anemia with a baseline hemoglobin <13 g/dL was associated with a more than 5-fold increased risk for contrast-induced acute kidney injury in patients undergoing coronary angiography.
The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data which demonstrated a high degree of similarity between Retacrit and its reference product.
Using the infarct heat map, the investigators determined that infarct density was higher in the deep white matter and co-localized with the elevated OEF region in the independent prospective cohort.
In this post hoc analysis, researchers explored whether anemia was a predictor of radiographic progression in patients with RA who were treated with tofacitinib.
The researchers found that OS was superior in IST responders. Shorter relapse-free survival (RFS) was seen with partial response to IST compared with complete response.
Other biologic DMARDs were not associated with any significant clinically meaningful increase in Hb and Hct levels.
Low hemoglobin levels independently predicted all-cause, cardiovascular, and noncardiovascular mortality in patients with coronary artery disease.